Trial Profile
Study of the Safety, Tolerability and Pharmacokinetics of LY3016859 After Single Intravenous and Subcutaneous Dosing in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fepixnebart (Primary) ; Fepixnebart (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Jan 2018 Results from two initial early-phase clinical studies(TGAA; NCT01545583 and TGAB; NCT01774981), published in the Clinical Pharmacology in Drug Development Journal.
- 13 Jun 2014 New trial record